Pfizer and BioNTech have reached an agreement with the European Commission (EC) to supply 200 million doses of their investigational mRNA-based vaccine candidate BNT162b2 against the SARS-CoV-2 virus that causes Covid-19.
In September, the companies concluded exploratory talks with the EC to provide doses of the candidate vaccine, if approved, and the latest supply agreement is now final.
Under the agreement, Pfizer and BioNTech will supply BNT162b2 to European Union (EU) member states.
The EC also has an option to request an additional 100 million doses of the vaccine candidate.
Subject to clinical success and regulatory clearance, deliveries are expected to begin later this year.
The vaccine doses will be manufactured at BioNTech’s manufacturing sites in Germany and Pfizer’s Belgium site for supply in Europe.
After receiving approval from the European Medicines Agency (EMA), doses of candidate vaccine BNT162b2 will be ordered by EU Member States.
Pfizer President and CEO Albert Bourla said, “Since the start of the pandemic, Pfizer’s priority has been to develop a safe and effective vaccine, while increasing our production to provide doses by the end of the year. ‘year.
“The supply agreement finalized today with the European Commission represents the largest initial vaccine dose order for Pfizer and BioNTech to date and an important step towards our common goal of making a Covid-19 vaccine available to vulnerable populations. “.
Based on current projections, Pfizer and BioNTech are expected to produce up to 50 million doses of the vaccine this year and up to 1.3 billion doses next year worldwide.
Last month, Pfizer and BioNTech initiated a rolling submission to the European Medicines Agency (EMA) for BNT162b2.